GSK Lotronex: 20% Of Scripts Come From Physicians Outside Of Risk Management Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
A survey completed by 36% of all Lotronex patients found they were very aware of the risks of the IBS therapy. FDA says it is too early to evaluate the overall effectiveness of the risk management program.
You may also be interested in...
Novartis Zelnorm Revised Labeling Includes Diarrhea Warning, Ischemic Colitis Precaution
The warning is the first in tegaserod labeling; Zelnorm was approved in 2002 without a warnings section. FDA has received 20 post-marketing reports of ischemic colitis; GSK’s Lotronex was withdrawn in 2000 following 49 reports.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).